Rodent model microbiomes introduce confounding effects in an alarming range of study endpoints. The intestinal microbiome is now understood to be a significant mediator of systemic antitumor immunity/response, in both naïve and treatment contexts.The Microbiome in Preclinical Immuno-oncology Research
In this exclusive Taconic Biosciences webinar, you will learn how the microbiome mediates antitumor immune response – and how controlling for these effects is critical to the reproducibility of your research.- How does the microbiome impact immunotherapy responses?
- Can you characterize the immune response based on microbiome composition?
- Can we modulate the intestinal microbiome to improve antitumor immune response?
Presenter:
Dr. Benjamin Cuiffo joined Biomodels in 2015 after completing his postdoctoral studies at Beth Israel Deaconess Medical Center and Harvard Medical School, where he was an American Cancer Society Fellow.As the Lead Oncology Scientist at Biomodels, Dr Cuiffo will collaborate with clients to design and execute clinically translational preclinical Oncology studies.
He received his Ph.D. in Molecular and Cell Biology from Brandeis University in 2010, where he developed novel strategies to target the RAS oncogene in animal models of leukemia. His postdoctoral work centered upon elucidating the molecular mechanisms of tumor metastasis in preclinical in vitro and in vivo models. Dr. Cuiffo has cultivated additional expertise in the biology of tumor- initiating (cancer stem cells) and invasive phenotypes, oncogenic signaling pathways, and noncoding RNAs in cancer.
Watch Now!
